Douglas J Fraser-Pitt (Douglas Fraser-Pitt)

Years Active: 2016-2022
Publications (10 Years): 5

NovaBiotics Ltd

University of Liverpool (BSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

NovaBiotics Ltd Feb 1o 2015

United Kingdom

Principal Scientist

Education History

University of Liverpool Sep 1o 1996 - Jun 30o 1999

United Kingdom

BSC :: Life Sciences

Publications

Derry K Mercer, Marie-Louise Francis, Douglas J Fraser-Pitt
Antimicrobial immunotherapeutics: past, present and future. Emerging topics in life sciences 5 (5) (2022)
Douglas J Fraser-Pitt, Derry K Mercer
What role for cysteamine in the defence against infection? Emerging topics in life sciences 5 (5) (2022)
Graham Devereux, Danielle Wrolstad, Stephen J Bourke, Cori L Daines, Simon Doe, Ryan Dougherty, Rose Franco, Alastair Innes, Benjamin T Kopp, Jorge Lascano, Daniel Layish, Gordon MacGregor, Lorna Murray, Daniel Peckham, Vincenzina Lucidi, Emma Lovie, Jennifer Robertson, Douglas J Fraser-Pitt, Deborah A O'Neil
Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial. PloS one 15 (12) (2020)
Douglas J Fraser-Pitt, Derry K Mercer, Daniel Smith, Aleksandra Kowalczuk, Jennifer Robertson, Emma Lovie, Peter Perenyi, Michelle Cole, Michel Doumith, Robert L R Hill, Katie L Hopkins, Neil Woodford, Deborah A O'Neil
Cysteamine, an Endogenous Aminothiol, and Cystamine, the Disulfide Product of Oxidation, Increase Pseudomonas aeruginosa Sensitivity to Reactive Oxygen and Nitrogen Species and Potentiate Therapeutic Antibiotics against Bacterial Infection. Infection and immunity 86 (6) (2018)
Douglas J Fraser-Pitt, Derry Mercer, Emma Lovie, Jennifer Robertson, Deborah O'Neil
Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex. Antimicrobial agents and chemotherapy 60 (10) (2016)

Douglas J Fraser-Pitt.css-eqlu8i{font-size:small;padding-left:4px;} (Douglas Fraser-Pitt)